The company said its product is bioequivalent and therapeutically equivalent to ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), the reference listed drug of Provepharm SAS.

Citing IQVIA sales data, Glenmark noted that the ProvayBlue injection market recorded annual sales of about $19 million for the 12-month period ended April 2026.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'the launch of Methylene Blue Injection USP reflects Glenmark's ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.'

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25.

The counter fell 1.31% to Rs 2,128.50 on the BSE.

Powered by Capital Market - Live News